Sector News

Report: Embattled blood-testing company Theranos lays off most remaining workers

April 11, 2018
Life sciences

Theranos has laid off most of its remaining workforce as it seeks to preserve cash and delay a bankruptcy filing for a few months, the Wall Street Journal reported Tuesday.

The layoffs reduced the Palo Alto, California-based blood-testing company’s staff from about 125 employees to fewer than two dozen workers, according to the report.

The company did not immediately return messages about the reported employee cuts.

The private company made Arizona its main testing grounds in 2013 when it began to roll out its unproven technology at Walgreens stores across metro Phoenix. The company opened 40 Theranos Wellness Centers in metro Phoenix and operated a laboratory at Arizona State University’s SkySong office complex in Scottsdale.

Theranos also successfully lobbied for a bill that allowed consumers to order any test without a doctor’s orders. Gov. Doug Ducey and legislative leaders joined Theranos founder and CEO Elizabeth Holmes for a bill-signing ceremony at Theranos’ Scottsdale lab.

But media reports and government regulators began to reveal problems with the company’s blood-testing technology.

Walgreens closed the 40 wellness centers and Theranos shut down its Scottsdale lab at SkySong.

Last month, the Securities and Exchange Commission said that Holmes and the company’s former President Ramesh “Sunny” Balwani conducted an “elaborate, years-long fraud” that deceived investors by claiming the company had developed a portable blood analyzer that could perform a range of tests from a small sample of blood.

By Ken Alltucker

Source: USA Today

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend